Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Introduction to Hemostasis01:05

Introduction to Hemostasis

8.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.4K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Coagulation01:09

Coagulation

7.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usefulness of Clot Waveform Analysis-Activated Thromboplastin Time (APTT) for Diagnosing Thrombotic Diseases.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Recognizing Coagulation Disorders in Sepsis in the Emergency Room: A Narrative Review.

Journal of clinical medicine·2026
Same author

Evaluation of Autoimmune FVIII Inhibitor Using Clot Waveform Analysis in Emicizumab-Treated Patients.

Journal of clinical medicine·2026
Same author

Diagnostic and Prognostic Evaluation of Disseminated Intravascular Coagulation Using the Disseminated Intravascular Coagulation Index.

Journal of clinical medicine·2025
Same author

Factors influencing antithrombin activity following supplementation in sepsis-associated disseminated intravascular coagulation.

Thrombosis journal·2025
Same author

Clinical Application of Clot Waveform Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2025

Related Experiment Video

Updated: Jul 25, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.9K

Clot Waveform Analysis for Hemostatic Abnormalities.

Hideo Wada1, Katsuya Shiraki1, Takeshi Matsumoto2

  • 1Department of Laboratory and General Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.

Annals of Laboratory Medicine
|June 30, 2023
PubMed
Summary
This summary is machine-generated.

Clot waveform analysis (CWA) offers insights into hemostatic abnormalities by examining clotting test waveforms. Modified CWA techniques show promise in evaluating hypercoagulability and hypocoagulability in various clinical conditions.

Keywords:
Clot waveform analysisFibrinolysisHemostasisHemostaticsIndicators and reagentsProthrombin timeThrombinThrombocytopeniaThrombophiliaThrombosis

More Related Videos

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

1.0K

Related Experiment Videos

Last Updated: Jul 25, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.9K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

1.0K

Area of Science:

  • Hematology
  • Clinical Pathology
  • Biomedical Engineering

Background:

  • Clot waveform analysis (CWA) assesses plasma transparency changes during clotting tests like APTT, PT, and TT.
  • Abnormal waveforms, peak times, and heights in CWA derivative curves are valuable for diagnosing hemostatic abnormalities.

Purpose of the Study:

  • To review routine and modified Clot Waveform Analysis (CWA) techniques.
  • To discuss the clinical applications of CWA in evaluating hemostatic function.

Main Methods:

  • Analysis of routine CWA based on activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT).
  • Review of modified CWA methods, including PT with APTT reagent, dilute PT (sTF/FIXa), and dilute TT.
  • Examination of derivative curves, peak times, and heights for diagnostic information.

Main Results:

  • CWA-sTF/FIXa: Elevated peak heights correlate with hypercoagulability (e.g., cancer, thrombosis); prolonged peak times indicate hypocoagulability (e.g., factor deficiency, thrombocytopenia).
  • CWA-dilute TT reflects the thrombin burst.
  • Clot-fibrinolysis waveform analysis assesses both hemostasis and fibrinolysis.

Conclusions:

  • Routine and modified CWA provide valuable data for assessing hemostatic abnormalities.
  • Further investigation is needed to establish the clinical relevance and utility of CWA-APTT and modified CWA across diverse diseases.